Joint Microbiome Study for the Knee

Sponsor
Rothman Institute Orthopaedics (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05254145
Collaborator
(none)
100
1
12.3
8.2

Study Details

Study Description

Brief Summary

Prosthetic joint infection (PJI) is a devastating complication following arthroplasty. An utmost effort has been done to clarify risk factors and microbiology of PJI. We now know the most frequent infecting microorganisms are members of the skin microbiome. These microorganisms are thought to get into the joint and infect the prosthesis during the peri-operative and/or post-operative period. Nevertheless, recent studies have suggested, bacteria may be present in the joint even before the first incision, suggesting the existence of a joint microbiome. Therefore, we aimed to determine the bacterial composition from different knee conditions.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Next Generation Sequencing

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Insight of Joint Microbiome From Different Knee Conditions.
Anticipated Study Start Date :
Feb 20, 2022
Anticipated Primary Completion Date :
Feb 28, 2023
Anticipated Study Completion Date :
Feb 28, 2023

Arms and Interventions

Arm Intervention/Treatment
Group A

This group will include participants without an arthritic knee. These participants will be recruited from the Orthopedic Sports Medicine consultation

Diagnostic Test: Next Generation Sequencing
During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Group B

This group will include participants undergoing primary knee arthroplasty (KA).

Diagnostic Test: Next Generation Sequencing
During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Group C

This group will include participants undergoing a surgical procedure whose opposite knee has no history of arthritis

Diagnostic Test: Next Generation Sequencing
During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Group D

This group will include participants undergoing knee revision surgery with no suspicion of infection (aseptic knee revision replacement)

Diagnostic Test: Next Generation Sequencing
During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Group E

This group will include participants undergoing knee revision with a known infection (septic knee revision replacements)

Diagnostic Test: Next Generation Sequencing
During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Outcome Measures

Primary Outcome Measures

  1. Determine the microbiome (bacterial composition) of the knee joint [3 days]

    Joint fluid taken from the operative knee during surgery will be analyzed using next generation sequencing (NGS).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • All patients 18 years or older who give verbal and written informed consent for the retrieval of experimental samples and data collection.

  • Group A: Subjects with lack of Osteoarthritis (OA) evidence, invasive examinations, minor procedures, cartilage damage, and/or synovitis in joints.

  • Group B: Patients undergoing primary knee arthroplasty (partial or total).

  • Group C: Contralateral non-affected (native) joint without knee arthroplasty, history of septic arthritis (SA), invasive examinations and/or minor procedures.

  • Group D: Patients undergoing aseptic knee revision surgery.

  • Group E: Patients undergoing septic knee revision surgery

Exclusion Criteria:
  • Withdrawal of informed consent, suspicion of PJI, surgical site infection (SSI) or septic arthritis (SA) before samples retrieval, use of antibiotics within 4 weeks before collecting the samples (not including perioperative antimicrobial prophylaxis), inflammatory arthritis, systemic rheumatic disorder, high risk of infection.

  • Group A: History and/or suspicion before/at samples retrieval of SA in native joint.

  • Group B: History and/or suspicion before/at samples retrieval of SSI or SA in the affected joint.

  • Group C: No additional criterion.

  • Group D: History and/or suspicion before/at samples retrieval of PJI, SSI, SA in the affected joint

  • Group E: No additional criterion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rothman Orthopaedic Institute Philadelphia Pennsylvania United States 19107

Sponsors and Collaborators

  • Rothman Institute Orthopaedics

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rothman Institute Orthopaedics
ClinicalTrials.gov Identifier:
NCT05254145
Other Study ID Numbers:
  • JPAR22D.042
First Posted:
Feb 24, 2022
Last Update Posted:
Feb 24, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 24, 2022